Norovirus GI.1 (NoV GI.1)

Norovirus GI.1, specifically represented by the prototype Norwalk virus, is a significant human pathogen within the Caliciviridae family [11]. It is a non-enveloped, single-stranded, positive-sense RNA virus and a leading cause of acute gastroenteritis outbreaks globally [21]. The viral genome encodes several key proteins that serve as therapeutic targets, including the major capsid protein (VP1), which is the primary antigen for vaccine development, and the RNA-dependent RNA polymerase (RdRp), which is essential for viral replication [6, 12]. GI.1 strains typically bind to host cell histo-blood group antigens (HBGAs) to facilitate entry, making host secretor status (determined by the FUT2 gene) a critical determinant of susceptibility [20, 22]. Therapeutic strategies focus on the development of virus-like particle (VLP) vaccines to induce neutralizing antibodies and small-molecule inhibitors targeting the RdRp and viral protease [8, 17]. Despite its clinical significance, there are currently no FDA-approved vaccines or specific antivirals, with treatment primarily focused on oral rehydration and symptom management [23].

Other names

Norwalk virusNVNorwalk-like virusGenogroup I genotype 1 norovirusWinter vomiting bug

Inhibition of RNA-dependent RNA polymerase (RdRp), inhibition of viral protease (3CLpro), blocking of viral attachment to histo-blood group antigens (HBGAs), and induction of neutralizing antibodies against the major capsid protein (VP1).